Safety and imaging study of a PET scan agent in metastatic breast cancer
Tests a PET imaging agent, [68Ga]Ga DOTA-5G, in adults with metastatic breast cancer.
Plain-language title generated from the registry record
Registry title: Safety and Biodistribution of [68Ga]Ga DOTA-5G in Subjects With Metastatic Breast Cancer (BC)
Key facts
- Where
- Nedlands, AustraliaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 89 years old?
Source: NCT07915297, who can take part
Where in Australia
- Icon Cancer CenterNedlands, AustraliaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Luminance Biosciences Inc
- Trial code
- NCT07915297
- Record updated
- 4 November 2026
- Original description
This is a prospective study using [68Ga]Ga DOTA-5G PET/CT imaging in patients diagnosed with metastatic breast cancer (BC).Read full original descriptionShow less
A Phase I Study to Evaluate the Safety and Biodistribution of [68Ga]Ga DOTA-5G in Subjects With Metastatic Breast Cancer (BC)
This is a prospective study using [68Ga]Ga DOTA-5G PET/CT imaging in patients diagnosed with metastatic breast cancer (BC).
Inclusion: Ability to understand and willingness to sign a written informed consent document; Men and women age ≥ 18 yrs; Confirmed presence of metastatic breast cancer; Eastern Cooperative Oncology Group Performance Status ≤ 2; Hematologic parameters defined as:; Absolute neutrophil count (ANC) ≥ 1x 109 /L,; Platelet count ≥ 100x 109 /L,; Hemoglobin ≥ 80 g/L; Blood chemistry levels defined as:; AST, ALT, alkaline phosphatase ≤ 5 times upper limit of normal (ULN),; Total bilirubin ≤ 2 times ULN,; Creatinine ≤ 2 times ULN; Anticipated life expectancy ≥ 3 months; Able to remain motionless for up to 30-60 minutes per scan.
Exclusion: Concurrent malignancy of a different histology that could confound imaging interpretation; Pregnant and lactating women; Prisoners; Patients who cannot undergo PET/CT scanning because of weight limits(>450lbs).